% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • blehair Jun 24, 2013 12:04 PM Flag

    Why +FEV1% improvements shown from inhaler trials are quite significant...

    CF lung function deteriorates continuously. FEV1 normal function is more than 80%, while severe cases are less than 40%, and transplant qualifications are met at 20%.

    The simple fact for CF sufferers is that it ends with death or transplants because lung function becomes too poor.

    Considering placebo arms consistently perform at 0% or lower +FEV1% improvement levels illustrates how significant even 1% superiority in an inhaler arm can be for sufferers. That could perpetually stave off the less than 25% FEV1% level from being hit years, even more than a decade.

    That's why TOBI, despite it's relatively bad efficacy now, will continue to rack in excess of $400M.

    Don't undervalue the impact that these inhalers have, even if it's a few percentages.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
9.88+0.16(+1.65%)Jun 29 4:00 PMEDT